Press "Enter" to skip to content

Pfizer gets U.S. approval for $225,000 a year heart drug

Pfizer, which has touted tafamidis as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under the brand name Vyndaqel.

Original source:

Also Read:   Four killed in attacks against Ebola response centers in Congo